Scholars Central

Short communicationPublished 21 Jun 2020

Bone Metastases in Metastatic Renal Cell Carcinoma: Now We Know That Cabozantinib Targets Bone Microenvironment

Authors: Giuseppe Procopio

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The multiple tyrosine kinases inhibitor cabozantinib has shown improvements in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in comparison to everolimus in patients with metastatic renal cell carcinoma (mRCC) within the METEOR trial, a phase III clinical trial , randomized, open-label trial [1,2], resulting in its approval in mRCC patients previously treated with antiangiogenic agents.

Subjects

Surgery

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Transplant Reports : Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalTransplant Reports : Open Access
  • SubjectSurgery
  • BylineArticles whose byline prints “Giuseppe Procopio”